MindMed Reveals Results Of A Study On Personalized MDMA Dosing

Psychedelic medicine biotech company MindMed (NEO: MMED) (OTCQB: MMEDF) (DE: MMQ) reported Monday the results of a study on MDMA dosing optimization utilizing personalized medicine.

The study was conducted at the University Hospital Basel Liechti Lab, in Basel, Switzerland. The company said it offers “the first scientific” information for predicting reactions to MDMA and optimizing dosing.

These results could help take full advantage of the medical benefits of the treatment, and minimize adverse reactions.

Key Findings

  • Predictors known prior to dosing, such as body weight, sex, genetics, age, personality trait measures and mood before treatment could help with MDMA dose …

Full story available on Benzinga.com

More MindMed Reveals Results Of A Study On Personalized MDMA Dosing